-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Special Session on Sickle Cell Disease Centers

Program: Special-Interest Sessions
Hematology Disease Topics & Pathways:
Sickle Cell Disease, Biological therapies, Clinical Practice (Health Services and Quality), Workforce, Diversity, Equity, and Inclusion (DEI) , Hemoglobinopathies, Diseases, Gene Therapy, Therapies
Saturday, December 9, 2023: 9:30 AM-11:00 AM
Hall A (San Diego Convention Center)

Lecture Title:
Looking for Money in All the “Right” Places for Sickle Cell

Payal Desai, MD, Atrium Health and Julie Kanter, MD, University of Alabama At Birmingham
Desai: University of Pittsburgh: Research Funding; University of Tennessee: Research Funding; POC Detection of Hemoglobin Sickling via Magnetic Fractionation: Patents & Royalties: (Pending); US Food & Drug Administration: Research Funding; NIH: Research Funding; Novartis: Research Funding, Speakers Bureau; Chiesi: Consultancy; PCORI: Research Funding; Vertex: Consultancy; Forma Therapeutics: Consultancy. Kanter: Chiesi: Honoraria, Membership on an entity's Board of Directors or advisory committees; Austin Therapeutics: Honoraria, Membership on an entity's Board of Directors or advisory committees; Bausch: Honoraria; Watkins, Lourie, Roll&Chance: Consultancy; Guidepoint Global: Consultancy; Fulcrum: Consultancy; ECOR1: Consultancy; Beam: Consultancy, Honoraria; OptumRx: Consultancy; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Bluebird Bio: Consultancy; GLG: Consultancy; Cowen: Consultancy.
As care for people with sickle cell disease gets more complex and there are more treatment options available, it is imperative that all people with SCD receive care through a sickle cell center.

Over the last several years, ASH has developed a workshop and blueprint for the creation of Sickle Cell Disease Centers. Despite their necessity, it can still be difficult to ensure funding for these centers. This session will focus on alternative ways to supplement funding for sickle cell disease centers.

Sophie Lanzkron

Johns Hopkins Medical Institute, Baltimore, MD

Julie Kanter, MD

Division of Hematology and Oncology, University of Alabama At Birmingham, Birmingham, AL

Alexis Kristine Leonard, MD

St. Jude Children's Research Hospital, Memphis, TN